News
NURO
4.400
0.00%
0.000
Weekly Report: what happened at NURO last week (0429-0503)?
Weekly Report · 2d ago
Weekly Report: what happened at NURO last week (0422-0426)?
Weekly Report · 04/29 11:44
Weekly Report: what happened at NURO last week (0415-0419)?
Weekly Report · 04/22 11:32
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Mobile-health Network (NASDAQ:MNDR) shares increased by 34.7% to $27.44 during Friday's regular session. NKGen Biotech stock increased by 19.76% and Adlai Nortye stock moved upwards by 16.33%. Other losers include SeaStar Medical Holding and iSpecimen.
Benzinga · 04/19 16:31
NeuroMetrix Rises 18% After Announcement Of Shareholder Value Enhancement Steps
NASDAQ · 04/19 15:07
Predictive Oncology, BIMI Holdings, IMAC Holdings among healthcare movers
Seeking Alpha · 04/19 14:00
NeuroMetrix names new independent director, terminates equity program; shares up
Seeking Alpha · 04/19 13:10
NeuroMetrix Board Appointment and Equity Program Termination
TipRanks · 04/19 12:22
NEUROMETRIX INC - APPROVED APPOINTMENT OF JOSHUA S. HOROWITZ AS A NEW INDEPENDENT DIRECTOR WITH A 1-YEAR TERM
Reuters · 04/19 12:00
Press Release: NeuroMetrix Announces Steps Taken to Enhance Shareholder Value
NeuroMetrix Announces Steps Taken to Enhance Shareholder Value Joshua S. Horowitz joins Board of Directors at-the-market equity facility terminated. The Board has approved the appointment of Joshua Horowitz as a new independent director with a 1-year term. The Company has also terminated its at- the- market equity facility with Echo Lake Capital.
Dow Jones · 04/19 12:00
NeuroMetrix Announces Steps Taken to Enhance Shareholder Value
Joshua S. Horowitz joins Board of Directors at-the-market equity facility terminated. NeuroMetrix, Inc. Announced two steps to enhance shareholder value. Echo Lake Capital's Ephraim Fields is one of the company's largest shareholders. The company's stock price is expected to rise.
Barchart · 04/19 07:00
Weekly Report: what happened at NURO last week (0408-0412)?
Weekly Report · 04/15 11:23
Weekly Report: what happened at NURO last week (0401-0405)?
Weekly Report · 04/08 11:28
Weekly Report: what happened at NURO last week (0325-0329)?
Weekly Report · 04/01 11:25
Weekly Report: what happened at NURO last week (0318-0322)?
Weekly Report · 03/25 11:28
Weekly Report: what happened at NURO last week (0311-0315)?
Weekly Report · 03/18 11:26
NeuroMetrix Announces That Over 2000 Patients With Fibromyalgia Have Been Prescribed Quell Fibromyalgia
Over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in December 2022. The device is a transcutaneous electrical nerve stimulation device indicated to reduce the symptoms of fibromyalgia in adults with high pain sensitivity. NeuroMetrix says the company is pleased with the positive response to the product.
Benzinga · 03/13 13:08
Weekly Report: what happened at NURO last week (0304-0308)?
Weekly Report · 03/11 11:23
Echo Lake Capital Calls For The Liquidation Of Neurometrix, Inc. "Notes Tremendous Destruction Of Shareholder Value Under Co's Leadership; Sees No Reason For Co To Remain Public"
Ephraim Fields of Echo Lake Capital wrote a letter to the Board of Directors of Neurometrix, Inc. He believes the company should immediately liquidate because its stock price is trading significantly below its net cash per share. Notes tremendous destruction of shareholder value under company's leadership. Sees no reason for company to remain public.
Benzinga · 03/04 13:08
Weekly Report: what happened at NURO last week (0226-0301)?
Weekly Report · 03/04 11:26
More
Webull provides a variety of real-time NURO stock news. You can receive the latest news about Neurometrix Inc through multiple platforms. This information may help you make smarter investment decisions.
About NURO
NeuroMetrix, Inc. is a commercial-stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two commercial brands. Quell is a wearable neuromodulation platform. DPNCheck is a point-of-care screening test for peripheral neuropathy. It operates two product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. Its patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud.